Given LEDGF/p75’s critical functions and protein interactions in cancer cells that promote tumor aggressiveness, there is a compelling argument for targeting this oncoprotein for cancer treatment, particularly for attenuating chemotherapy resistance. Here, PSIP1 is linked to neoplasm.